SCHEMBL216070

SCHEMBL216070

Cc1ccc(N(C(=O)c2nc[nH]c2C(N)=O)c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
RAB9A P51151 5/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 4/20 0.38
PKM P14618 1/20 0.38
OPRK1 P41145 1/20 0.38
KLF5 Q13887 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
MAPT P10636 4/20 0.37
KMT2A Q03164 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
MEN1 O00255 2/20 0.37
CYP2C9 P11712 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HPGD P15428 3/20 0.36
HTT P42858 1/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215785 0.89 POLB (0.41) POLBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL216562 0.89 POLB (0.64) POLBRAB9AKDM4ENPC1PKM
SCHEMBL216492 0.87 POLB (0.37) POLBRAB9AKDM4ENPC1PKM
SCHEMBL217227 0.87 POLB (0.37) POLBRAB9AKDM4ENPC1PKM
SCHEMBL214715 0.87 POLB (0.40) POLBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL215596 0.84 POLB (0.38) POLBRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL215700 0.84 SMN1; SMN2 (0.40) RAB9AKDM4ENPC1PKMOPRK1
SCHEMBL213504 0.84 POLB (0.38) POLBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL214873 0.83 LMNA (0.39) POLBRAB9AKDM4ENPC1PKM
SCHEMBL215369 0.83 POLB (0.41) POLBRAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885RAB9A 2213/4885KDM4E 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.